INT23426

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1985
Last Reported 2008
Negated 2
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 1.81
Pain Relevance 1.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ADRA2A) small molecule metabolic process (ADRA2A) plasma membrane (ADRA2A)
cytoplasm (ADRA2A) signal transducer activity (ADRA2A)
Anatomy Link Frequency
platelet 3
thyroid 1
ADRA2A (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 14 99.98 Very High Very High Very High
antagonist 6 99.96 Very High Very High Very High
noradrenaline 4 95.84 Very High Very High Very High
agonist 16 92.00 High High
Dysuria 1 83.96 Quite High
Analgesic 1 35.56 Quite Low
Lasting pain 2 5.00 Very Low Very Low Very Low
central sensitization 1 5.00 Very Low Very Low Very Low
Acute pain 1 5.00 Very Low Very Low Very Low
hypoalgesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 8 100.00 Very High Very High Very High
Body Weight 3 99.40 Very High Very High Very High
Overactive Bladder 1 97.52 Very High Very High Very High
Hyperplasia 1 94.56 High High
Benign Prostatic Hypertrophy 2 93.80 High High
Thyroid Disease 4 89.88 High High
Pain 3 86.64 High High
Pressure Volume 2 Under Development 1 77.84 Quite High
Alzheimer's Dementia 3 75.00 Quite High
Urological Neuroanatomy 2 61.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Neither acute (2 micrograms/kg body weight) nor subchronic (3 days, 2 x 150 micrograms/kg body weight) administration of clonidine affected platelet alpha 2-adrenoceptor number in humans as judged by 3H-yohimbine and 3H-UK-14,304 binding.
Neg (Neither) Regulation (affected) of alpha 2-adrenoceptor in platelet associated with body weight and clonidine
1) Confidence 0.48 Published 1993 Journal Pharmacology Section Abstract Doc Link 8382822 Disease Relevance 0.39 Pain Relevance 0.55
Effects of alpha-adrenoceptor and muscarinic receptor active drugs were studied.
Regulation (Effects) of alpha-adrenoceptor
2) Confidence 0.42 Published 1985 Journal J. Urol. Section Abstract Doc Link 2414474 Disease Relevance 0.28 Pain Relevance 0.36
The effects of tetramethylpyrazine on the human platelet alpha 2 adrenergic receptor adenylate cyclase system.
Regulation (effects) of alpha 2 adrenergic receptor in platelet
3) Confidence 0.39 Published 1987 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Title Doc Link 2829329 Disease Relevance 0 Pain Relevance 0.15
This protocol was performed under placebo and alpha-2 adrenergic (ADRA2) blockade with yohimbine in counterbalanced order to test for the influence of ADRA2 mechanisms.
Regulation (influence) of ADRA2
4) Confidence 0.38 Published 2008 Journal Anesth. Analg. Section Body Doc Link 18713923 Disease Relevance 0.09 Pain Relevance 0
Alpha 2-adrenergic receptor-mediated regulation of adenylate cyclase in the intact human platelet.
Regulation (regulation) of 2-adrenergic in platelet
5) Confidence 0.17 Published 1985 Journal Mol. Pharmacol. Section Title Doc Link 2981397 Disease Relevance 0 Pain Relevance 0.22
It is concluded that the inhibitory alpha 2-receptor pathway functions normally in all groups, indicating that the alpha 2-receptors and the alpha 2-receptor-mediated pathway in human adipocytes are relatively unaffected by thyroid hormones.
Neg (unaffected) Regulation (unaffected) of alpha 2-receptor in thyroid associated with obesity
6) Confidence 0.12 Published 1987 Journal Metab. Clin. Exp. Section Abstract Doc Link 2823049 Disease Relevance 0.64 Pain Relevance 0.30
These results suggest a possible role of APLP1 in regulation of alpha2A-adrenergic receptor trafficking.
Regulation (regulation) of alpha2A-adrenergic
7) Confidence 0.09 Published 2006 Journal Cell. Signal. Section Abstract Doc Link 16531006 Disease Relevance 0.24 Pain Relevance 0.12
Cardiovascular effects of the selective alphalA-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction.
Regulation (effects) of alphalA-adrenoceptor associated with antagonist and overactive bladder
8) Confidence 0.01 Published 2006 Journal Arzneimittelforschung Section Title Doc Link 17225563 Disease Relevance 0.18 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox